5-Amino-1MQ: NNMT Inhibition and the Preclinical Fat-Metabolism Story

A quick honesty note before anything else: 5-Amino-1MQ is not a peptide. It is a small synthetic molecule — 5-amino-1-methylquinolinium, a quaternary ammonium salt built on a quinoline scaffold. It shows up in "peptide" catalogs and forums because it travels in the same research-chemical circles, but structurally it has nothing in common with the amino-acid chains we usually cover here. We keep a reference entry at /peptides/5-amino-1mq for that reason, but the label is a category error worth flagging up front.

With that out of the way, here is what the actual literature does and does not support.

The target: NNMT and the SAM/NAD+ economy

5-Amino-1MQ was designed as a selective inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT does one job: it transfers a methyl group from S-adenosylmethionine (SAM) onto nicotinamide, producing 1-methylnicotinamide (1-MNA). That single reaction sits at a metabolic crossroads. It consumes SAM (the cell's main methyl-donor), and it siphons nicotinamide away from the NAD+ salvage pathway. In tissues that over-express NNMT — notably white adipose tissue in obese animals — the theory is that a chronically busy NNMT drains both the SAM pool and the NAD+ pool, nudging fat cells toward storage rather than energy expenditure.

The hypothesis, then, is straightforward: block NNMT, and you should see intracellular 1-MNA fall while SAM and NAD+ rise. In cell culture, that is broadly what the medicinal-chemistry work reported.

What the preclinical data actually shows

The pivotal work is *Neelakantan and colleagues, published in Biochemical Pharmacology in 2018* — the first demonstration that a small-molecule NNMT inhibitor could reproduce metabolic effects previously seen only with antisense knockdown of the enzyme. Two layers of evidence are worth separating:

In cells (3T3-L1 adipocytes). Methylquinolinium inhibitors including 5-Amino-1MQ were membrane-permeable, lowered intracellular 1-MNA (confirming target engagement), and raised NAD+ modestly — reported in the range of roughly 1.2–1.6 fold versus untreated controls. Treated adipocytes showed reduced lipogenesis and smaller fat-droplet accumulation, even under conditions that normally drive fat storage.

In mice. In diet-induced obese C57BL/6 mice on a 60%-kcal-from-fat diet, 5-Amino-1MQ produced concentration-dependent reductions in fat mass and adipose-tissue NNMT activity, with smaller adipocytes, and did so without significant changes in food intake or lean mass. A separate short (≈11-day) proof-of-concept dosing scheme in DIO mice reported progressive body-weight loss versus controls. Some rodent work also noted improved glucose tolerance and insulin sensitivity on standard GTT/ITT testing.

The mechanistically interesting part is the appetite-independent signal. Most anti-obesity compounds work through satiety circuits; here the animals ate the same amount and still lost fat mass, which points toward the drug acting on adipose-tissue biology directly rather than on hunger. That is a genuinely different mechanism — and it is exactly the kind of clean, tidy result that deserves skepticism until it is reproduced by independent groups and, eventually, in humans.

Selectivity — a point in its favor, with a caveat

One reason 5-Amino-1MQ drew attention is reported selectivity: in the medicinal-chemistry testing it did not meaningfully inhibit related SAM-dependent methyltransferases or NAD+-salvage enzymes. That matters, because a blunt instrument that hit every methyltransferase would be a toxicology nightmare. But "selective in a biochemical panel" is not the same as "safe in a living human over months of dosing." NNMT and 1-MNA have signaling roles beyond fat cells — in vasculature and inflammation, for instance — and chronically shifting that axis has simply never been studied in people.

The evidence gap you cannot argue around

Here is the honest bottom line: there are no human clinical trials of 5-Amino-1MQ — none. Zero human efficacy data, zero human safety data, no published pharmacokinetics in humans, and no regulatory approval anywhere. Everything above is rodent and cell-culture work. The compound is orally active in mice, which is often cited as a selling point, but oral activity in a mouse tells you nothing reliable about dose, exposure, or risk in a human.

Material sold as 5-Amino-1MQ is offered strictly as a research chemical, not as a medicine, and its regulatory footing is exactly what you would expect for an unapproved investigational compound — see our note at /fda-status for how we frame that. Purity, identity, and dosing consistency across vendors are unverified variables on top of an already thin evidence base.

The research-log takeaway

5-Amino-1MQ is a mechanistically elegant NNMT inhibitor with a coherent story — lower 1-MNA, spare SAM and NAD+, less lipogenesis, smaller fat cells in mice — anchored to a real 2018 primary paper. That is more than many trend compounds can claim. But "promising in mice" is the beginning of a drug-development question, not the end. Treat it as an interesting preclinical signal, not an established fat-loss tool, and weigh the total absence of human data accordingly.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.